What is the new Lancet definition of menopause brain fog?

Self-reported cognitive impairment that is debilitating and impacts quality of life, occurring during the menopause transition, in the absence of notable objective cognitive decline. The clinical significance is that symptoms are real and clinically meaningful even when neuropsychological tests fall within the population reference range.

What can help menopause brain fog right now?

Contributing factors are targetable even before treatments for brain fog specifically are established: addressing sleep-disordered breathing and insomnia, managing vasomotor symptoms (including MHT discussion with your GP for eligible women), stabilising blood glucose, daily movement, and stress regulation. These are addressed in the /learn/perimenopause-brain post.

The Lancet has now defined menopause brain fog — here's what that changes

What just happened

A team led by Dr Caroline Gurvich at Monash University, with co-authors from the University of Melbourne and University College London, published a review in The Lancet Obstetrics, Gynaecology, & Women’s Health in April 2026 proposing the first formal clinical definition of menopause brain fog.

The definition is both precise and politically significant: self-reported cognitive impairment that is debilitating and impacts quality of life, occurring during the menopause transition, in the absence of notable objective cognitive decline.

Read that last clause again. The absence of notable objective decline does not disqualify the diagnosis. It is built into the definition.

Cross-sectional evidence reviewed in the paper finds that around two-thirds of women report cognitive concerns — memory loss, difficulty concentrating, word-finding failures, mental fatigue — during the menopause transition. Most of those women have been told, at some point, that their tests are normal. The paper — Australian-led, published in the Lancet — says: normal tests do not mean normal experience. That sentence is now peer-reviewed.

For the woman who has sat across from a GP and heard that her cognitive assessment came back within range: this paper is for her. And by “for her” I mean specifically: it is a clinical reference she can now put on the desk.

The both-and

The definition is a meaningful advance. The absence of treatments is the frontier. Both are true.

The clinical significance of a formal definition is not primarily semantic. It determines what gets measured, what gets treated, and what warrants Medicare coverage in the future. Before a symptom cluster has an agreed definition, researchers cannot run consistent trials on it — every study uses different inclusion criteria, different questionnaires, different thresholds. The MedicalXpress coverage of the Lancet paper summarised the researchers’ intent directly: redefining brain fog to pave the way for clinical studies. The definition is the prerequisite for the evidence.

The current state is that contributing factors are identified and some are addressable, but a treatment specifically for menopausal cognitive symptoms — as distinct from addressing the upstream factors — does not yet exist in the evidence base. The Lancet team named the contributing factors: neuroendocrine changes (particularly the erratic oestradiol signalling of the perimenopause transition), sleep disturbance, vasomotor symptoms such as night sweats interrupting sleep architecture, mood disorders with significant bidirectional overlap, and psychosocial stress load. These are not distinct; they compound each other.

The Australasian Menopause Society has long acknowledged that cognitive symptoms are among the most distressing and disruptive of the perimenopause presentation — but the clinical response has lagged because “brain fog” has not had the definitional status to generate consistent research or funding.

The tension to hold: the definition validates the experience and creates the infrastructure for future research. It does not, today, produce a new treatment. The frontier is now properly charted; the expedition has not yet returned.

2 cents

The practical value of this paper is in the consultation room, not the laboratory.

If you have been experiencing cognitive symptoms — word loss, memory gaps, concentration lapses, the sense that your brain is operating through fog — during the perimenopause transition, and you have been told your assessments are normal, you now have a Lancet paper with an Australian lead author that says: within-range testing is compatible with the diagnosis. The paper can be referenced. The diagnosis can be made.

The things that help while the treatment evidence develops are the same contributing factors the paper names, taken as levers:

Sleep is the highest-return target. Sleep-disordered breathing (which increases in perimenopause as progesterone falls and upper airway muscle tone changes) goes frequently undiagnosed in women. Night sweats fragment sleep architecture independently of breathing. Both can be assessed and addressed. Treating sleep is not an alternative to addressing the underlying hormonal transition; it is a significant lever in its own right.

Vasomotor symptom management — if night sweats or hot flushes are disrupting sleep or daily function, a discussion with a GP about menopausal hormone therapy is clinically warranted for eligible women. The Australasian Menopause Society supports this discussion. The cognitive symptoms often partially track alongside the vasomotor symptoms when those are well-managed.

Glucose stability and daily movement are the two other documented levers. Blood glucose variability amplifies brain fog in the perimenopause period; so does sedentary behaviour.

The Lancet definition makes the conversation with your GP about these symptoms more legitimate. Use that.

This is general information. The management of perimenopause cognitive symptoms is individual — it depends on symptom pattern, sleep history, cardiovascular risk, and much more. That conversation belongs with your GP.

Verdict

Verdict: yes — worth knowing about.

A Monash and Melbourne-led team has published the first formal clinical definition of menopause brain fog in The Lancet — establishing that the symptom is real and clinically significant even when objective tests are normal. Two-thirds of women report cognitive concerns during the menopause transition. The definition is a prerequisite for clinical trials and future treatments. In the consultation room now: the paper supports making the diagnosis on reported symptoms, and the contributing factors (sleep, vasomotor symptoms, mood, glucose stability) are the addressable levers available.